Home  »  Science   »  Is Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Wor...

Is Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) Worth Much? What Should Investors Do?

During the last session, Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)’s traded shares were 1.91 million. At the end of the trading day, the stock’s price was $24.61, reflecting an intraday gain of 10.81% or $2.4. The 52-week high for the ARQT share is $26.13, that puts it down -6.18 from that peak though still a striking 44.78% gain since the share price plummeted to a 52-week low of $13.59. The company’s market capitalization is $1.16B, and the average intraday trading volume over the past 10 days was 0.94 million shares, and the average trade volume was 519.58K shares over the past three months.

Arcutis Biotherapeutics Inc. (ARQT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.90. ARQT has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.42.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) trade information

Arcutis Biotherapeutics Inc. (ARQT) registered a 10.81% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 10.81% in intraday trading to $24.61 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 5.35%, and it has moved by 8.13% in 30 days. Based on these gigs, the overall price performance for the year is 18.32%. The short interest in Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is 3.92 million shares and it means that shorts have 7.43 day(s) to cover.

The consensus price target of analysts on Wall Street is $55.71, which implies an increase of 55.82% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $45.00 and $80.00 respectively. As a result, ARQT is trading at a discount of -225.07% off the target high and -82.85% off the low.

Arcutis Biotherapeutics Inc. (ARQT) estimates and forecasts

Statistics show that Arcutis Biotherapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Arcutis Biotherapeutics Inc. (ARQT) shares have gone up 65.61% during the last six months, with a year-to-date growth rate less than the industry average at -35.17% against 1.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -69.00% this quarter and then drop -28.90% in the quarter after that.

Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $660k by the end of Sep 2022.

While earnings are projected to return -9.80% in 2022, the next five years will return 9.80% per annum.

ARQT Dividends

Arcutis Biotherapeutics Inc. is due to release its next quarterly earnings between February 14 and February 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)’s Major holders

Arcutis Biotherapeutics Inc. insiders own 4.32% of total outstanding shares while institutional holders control 89.57%, with the float percentage being 93.62%. Frazier Life Sciences Management, L.P. is the largest shareholder of the company, while 190 institutions own stock in it. As of Mar 30, 2022, the company held over 8.43 million shares (or 16.40% of all shares), a total value of $162.44 million in shares.

The next largest institutional holding, with 7.56 million shares, is of FMR, LLC’s that is approximately 14.70% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $145.56 million.

Also, the Mutual Funds coming in first place with the largest holdings of Arcutis Biotherapeutics Inc. (ARQT) shares are Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.88 million shares. This amounts to just over 1.71 percent of the company’s overall shares, with a $16.89 million market value. The same data shows that the other fund manager holds slightly less at 0.87 million, or about 1.69% of the stock, which is worth about $18.13 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts